Immunome, Inc. ("Immunome") , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback